| Literature DB >> 21299911 |
Piret Kalmus1, Birgit Aasmäe, Age Kärssin, Toomas Orro, Kalle Kask.
Abstract
BACKGROUND: The goal of this study was to estimate the distribution of udder pathogens and their antibiotic resistance in Estonia during the years 2007-2009.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21299911 PMCID: PMC3041692 DOI: 10.1186/1751-0147-53-4
Source DB: PubMed Journal: Acta Vet Scand ISSN: 0044-605X Impact factor: 1.695
Zone diameter intepretive criteria
| Disc content in μg | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S | I | R | S | I | R | S | I | R | S | I | R | |
| Ampicillin 10 μg | ≥ 29 | - | ≤28 | ≥ 26 | 19-25 | ≤18 | ≥ 17 | - | ≤16 | ≥ 17 | 15-16 | ≤14 |
| Penicillin 10 μg | ≥ 29 | - | ≥ 29 | ≥24 | - | - | ≥15 | - | ≤14 | - | - | - |
| Cephalothin 30 μg | ≥ | ≤ | - | - | - | |||||||
| Cefaperazone 75 μg | - | - | - | - | - | - | - | - | - | ≥21 | 16-20 | ≤15 |
| Clindamycin 2 μg | ≥ 21 | 15-20 | ≥ 14 | ≥19 | 16-18 | ≤15 | - | - | - | - | - | - |
| Erythromycin 15 μg | ≥ 23 | 14-22 | ≥ 14 | ≥21 | 16-20 | ≤15 | - | - | - | - | - | - |
| Gentamycin 10 μg | ≥ 12 | 13-14 | ≥ 15 | ≥12 | 13-14 | 15≤ | ≥10 | 7-9 | ≤6 | ≥ 12 | 13-14 | ≥ 15 |
| Tetracycline 30 μg | ≥ 19 | 15-18 | ≥ 14 | ≥23 | 19-22 | ≤18 | ≥19 | 15-18 | ≤14 | ≥ 19 | 15-18 | ≥ 14 |
| Enrofloxacin 5 μg | ≥ 20 | 15-19 | ≤14 | |||||||||
| Trimethoprim/sulfa 1,25/23,75 μg | ≥ 16 | 11-15 | ≥ 10 | ≥16 | 11-15 | ≤10 | ≥16 | 11-15 | ≤10 | ≥ 16 | 11-15 | ≥ 10 |
Distribution of milk samples according to herd size
| Clinical mastitis | Subclinical mastitis | |||||||
|---|---|---|---|---|---|---|---|---|
| 1 (1-30 cows) | 54 | 28.4 | 98 | 3.2 | 41 | 15 | 86 | 1.7 |
| 2 (31-99 cows) | 35 | 18.4 | 149 | 4.9 | 51 | 18.6 | 268 | 5.2 |
| 3 (100-299 cows) | 40 | 21.1 | 378 | 12.4 | 53 | 19.3 | 541 | 10.5 |
| 4 (300-599 cows) | 44 | 23.2 | 1472 | 48.1 | 80 | 29.2 | 2426 | 47.1 |
| 5 (> 600 cows) | 17 | 8.9 | 961 | 31.4 | 49 | 17.9 | 1825 | 35.5 |
| Total | 190 | 100 | 3058 | 100 | 274 | 100 | 5146 | 100 |
Distribution of bacterial species isolated from clinical and subclinical mastitis samples in 2007-2009
| Clinical mastitis | Subclinical mastitis | |||||
|---|---|---|---|---|---|---|
| 11.7 | 11.7 | 11.7 | 19.2 | 22.8 | 16.6 | |
| CNS | 4.8 | 7.1 | 8.5 | 16.1 | 13.6 | 17.4 |
| CPS* | 3.8 | 3.3 | 1.6 | 4.6 | 2.8 | 5.1 |
| 9.0 | 11.3 | 14.7 | 13.6 | 9.0 | 10.7 | |
| 8.0 | 7.8 | 7.2 | 3.6 | 4.0 | 5.6 | |
| 16.1 | 21.8 | 17.1 | 10.2 | 12.3 | 12.9 | |
| 3.2 | 3.3 | 1.9 | 1.2 | 2.0 | 2.7 | |
| 10.9 | 3.9 | 5.7 | 8.9 | 8.2 | 3.9 | |
| 14.4 | 16.6 | 16.5 | 1.6 | 2.0 | 3.8 | |
| 7.0 | 1.3 | 2.3 | 0.7 | 0.6 | 0.9 | |
| 1.3 | 2.3 | 1.1 | 1.5 | 2.8 | 4.2 | |
| 2.2 | 2.6 | 5.0 | 16.5 | 17.3 | 8.5 | |
| 2.2 | 3.8 | 3.6 | 0.1 | 0.6 | 0.6 | |
| 1 | 0.3 | 0.3 | 0 | 0 | 0.6 | |
| 0.2 | 0 | 0.2 | 0.4 | 0.1 | 0.6 | |
| Yeast | 2.3 | 2 | 1.6 | 1.5 | 1.6 | 5.6 |
| Other | 1.8 | 0.9 | 1 | 0.3 | 0.3 | 0.3 |
| Total | 100% | 100% | 100% | 100% | 100% | 100% |
* CPS: coagulase-positive staphylococci (other than S. aureus)
Antimicrobial susceptibility of staphylococci isolated from bovine clinical mastitis
| CNS | ||||||||
|---|---|---|---|---|---|---|---|---|
| Ampicillin10 μg | 173 | 40.5 | - | 59.5 | 91 | 61.5 | - | 38.5 |
| Penicillin10 μg | 174 | 38.6 | - | 61.4 | 93 | 65.5 | - | 34.4 |
| Cephalothin 30 μg | 160 | 96.2 | - | 3.8 | 84 | 96.4 | - | 3.6 |
| Clindamycin 2 μg | 169 | 81.9 | 0 | 18.1 | 91 | 82.4 | 0 | 17.6 |
| Erythromycin15 μg | 83 | 95.2 | 0 | 4.8 | 47 | 85.1 | 0 | 14.9 |
| Tetracycline 30 μg | 147 | 95.9 | 0 | 4.1 | 86 | 88.4 | 0 | 11.6 |
| Trimethoprim/sulfa 1.25/23.75 μg | 162 | 96.6 | 0 | 3.4 | 76 | 97.4 | 0 | 2.6 |
| Gentamycin 10 μg | 146 | 93.2 | 0 | 6.8 | 69 | 98.6 | 0 | 1.4 |
* Propotion of susceptible (S), intermediate susceptibility (I) and resistant (R) isolates
Antimicrobial susceptibility of streptococci isolated from bovine clinical mastitis
| Ampicillin 10 μg | 162 | 100 | - | 0 | 111 | 100 | 0 | 0 | 265 | 99.6 | 0 | 0.4 |
| Penicillin 10 μg | 168 | 100 | - | 0 | 111 | 100 | 0 | 0 | 267 | 99.6 | 0 | 0.4 |
| Cephalothin 30 μg | 143 | 100 | - | 0 | 101 | 100 | 0 | 0 | 254 | 99.6 | 0 | 0.4 |
| Clindamycin 2 μg | 161 | 91.9 | 1.9 | 6.2 | 115 | 92.2 | 0 | 7.8 | 273 | 92 | 1.4 | 6.6 |
| Erythromycin 15 μg | 77 | 96.1 | 2.6 | 1.3 | 60 | 88.3 | 5 | 6.7 | 134 | 89.6 | 2.2 | 8.2 |
| Tetracycline 30 μg | 151 | 78.1 | 7.3 | 14.6 | 90 | 48.9 | 18.9 | 32.2 | 234 | 79.9 | 3.4 | 19.7 |
| Trimethoprim/sulfa | 140 | 93.6 | 0 | 6.4 | 103 | 99 | 0 | 1 | 223 | 95.9 | 0.9 | 3.2 |
| Gentamycin 10 μg | 143 | 63.6 | 11.9 | 24.5 | 88 | 88.6 | 0 | 11.4 | 210 | 71.9 | 9.5 | 18.6 |
* Propotion of susceptible (S), intermediate susceptibility (I) and resistant (R) isolates
Antimicrobial susceptibility of E. coli and Klebsiella spp. isolated from bovine clinical mastitis
| Ampicillin 10 μg | 201 | 68.7 | 7.0 | 24.3 | 39 | 15.4 | 7.7 | 76.9 |
| Cefaperazone75 μg | 137 | 100 | 0 | 0 | 32 | 100 | 0 | 0 |
| Tetracycline 30 μg | 184 | 77.8 | 8.7 | 13.5 | 39 | 79.6 | 10.2 | 10.2 |
| Trimethoprim/sulfa 1.25/23.75 μg | 191 | 84.3 | 3.7 | 12.0 | 40 | 97.5 | 0 | 2.5 |
| Gentamycin 10 μg | 161 | 94.3 | 2.5 | 2.2 | 40 | 95.0 | 0 | 5.0 |
| Streptomycin 300 | 154 | 78.6 | 5.8 | 15.6 | 37 | 73.0 | 8.1 | 18.9 |
| Neomycin 30 μg | 155 | 72.9 | 20.6 | 6.5 | 37 | 83.8 | 13.5 | 2.7 |
| Enrofloxacin 5 μg | 185 | 98.4 | 0 | 1.6 | 37 | 100 | 0 | 0 |
* Proportion of susceptible (S), intermediate susceptibility (I) and resistant (R) isolates